Alpine Immune Sciences, Inc. (ALPN)

Clinical-stage biopharmaceutical company developing immunotherapies for autoimmune and inflammatory diseases.

ALPN Stock Quote

Company Report

Alpine Immune Sciences, Inc., headquartered in Seattle, Washington, is a clinical-stage biopharmaceutical company specializing in the research and development of protein-based immunotherapies. The company is dedicated to advancing treatments for a range of conditions, including cancer, autoimmune disorders, and inflammatory diseases. Alpine's innovative pipeline features several promising candidates, including ALPN-101, an antagonist targeting inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28), aimed at autoimmune and inflammatory conditions.

Additionally, Alpine is developing ALPN-202, a novel dual checkpoint inhibitor and conditional CD28 costimulator designed to enhance anti-tumor immune responses in cancer therapy. The company's portfolio also includes ALPN-303, a dual antagonist targeting B cell cytokines, intended for the treatment of autoimmune and inflammatory diseases mediated by B cells.

Alpine Immune Sciences collaborates with industry leaders such as AbbVie Ireland Unlimited Company for the development of ALPN-101, highlighting its commitment to advancing therapeutic solutions through strategic partnerships. Moreover, the company has partnered with Adaptimmune Therapeutics plc to explore next-generation SPEAR T cell products, underscoring its focus on leveraging cutting-edge technologies to innovate in the field of immunotherapy.

Founded in 2007, Alpine Immune Sciences has established itself as a leader in biopharmaceutical innovation, driven by a mission to harness the potential of protein-based therapies to transform patient care. With a strong emphasis on scientific excellence and collaboration, Alpine continues to expand its pipeline and pursue groundbreaking treatments that aim to improve outcomes and quality of life for patients worldwide.

ALPN EPS Chart

ALPN Revenue Chart

Stock Research

TELL BFI GTAC TPIC GNSS RRX DNMR

ALPN Chart

View interactive chart for ALPN

ALPN Profile

ALPN News

Analyst Ratings